A pharma-ceutical & digital therapeutics company

June 8 2022

Robert Rönn, SVP & Head of R&D

Orexo supports the UN's Agenda 2030 with a focus on:

Legal disclaimer

- This presentation, which is personal to the recipient, has been prepared and produced by Orexo AB (publ) (“Orexo”) solely for the benefit of investment analysis and may not be used for any purpose other than assessment of investments concerning Orexo. Unless otherwise stated, Orexo is the source for all data contained in this presentation. Such data is provided as at the date of this presentation and is subject to change without notice.
- This presentation does not constitute or form part of, and should not be construed as, an offer or invitation for the sale of or the subscription of, or a solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any offer, contract, commitment or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of Orexo
- The shares of Orexo have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act"), and may not be offered or sold in the United States (as such term is defined in Regulation S under the Securities Act) except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the Securities Act or unless registered under the Securities Act.
- The information in this presentation has not been independently verified. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information or opinions contained herein. None of Orexo, any of its shareholders, or any of their respective subsidiary undertakings or affiliates or any of such person’s directors, officers or employees, advisers or other representatives, accepts any liability whatsoever (whether in negligence or otherwise) arising, directly or indirectly, from the use of this presentation or otherwise arising in connection therewith.
- This presentation includes forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this presentation and Orexo expressly disclaim any obligation or undertaking to release any update of, or revisions to, any forward-looking statements in this presentation as a result of any change in our expectations or any change in events, conditions or circumstances on which these forward-looking statements are based.
- This presentation is not a prospectus in accordance with the Swedish Financial Instruments Trading Act (Sw. lagen (1991:981) om handel med finansiella instrument) or any other Swedish laws or regulations. Neither the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) nor any other Swedish regulatory body has examined, approved or registered this presentation.

Orexo in brief

US Pharma

Commercial US Pharma platform since 2013, incl. market access team and sales representatives who on a daily basis visit physicians, medical clinics and minor hospitals.

HQ & Pipeline

Development of improved drugs based on well-known substances combined with innovative proprietary Drug Delivery technologies, such as amorphOX®.



Digital Therapeutics

Evidence-based digital therapies grounded in cognitive behavioral therapy techniques, offer better treatment access for patients and improve their outcomes.

US Pharma

ZUBSOLV® for the treatment of opioid use disorder

ZUBSOLV® short facts

API	Buprenorphine/naloxone
Technology	Sublingual
Indication	Opioid use disorder
Market approvals	US, EU and Australia
US launch	2013
Commercial rights	Orexo owns global rights, ex EU
Partner EU	Accord Healthcare
Patent protection	US, EU, Australia and New Zealand until 2032

Product advantages include:

- Higher bioavailability
- Fast dissolve time
- Preferred menthol flavor
- Broadest range of dose strengths

zubsolv® sublingual tablets (buprenorphine and naloxone) C

The opioid crisis - one of the largest health crises ever in the US

10 million — Americans misusing opioids

4 million — In need of treatment

1.4 million — Under treatment

Overdose deaths have surpassed 107 000 in 2021, fueled by use of synthetic opioids such as fentanyl



Sources: Substance Abuse and Mental Health Services Administration, Clarion Healthcare, Center of Disease Control

"Giana made the switch to heroin, and it was all downhill from there."

Elise discovered her daughter's opioid addiction months before she died from an overdose.

Read more at the Orexo blog

ZUBSOLV® is an important cash generator

Accumulated net revenues

4.2 SEK billion

Since US launch 2013 – Q1 2022

US Pharma net revenues[2]

535 SEK M

LTM Q1 2022

Key operational highlights in Q1 2022

- ✓ ZUBSOLV® added to preferred NY Medicaid formulary from March 22
- ✓ Commercial market share in NY in Q1 was 10 percent[1] compared to Medicaid with ~0.5 percent
- ✓ Increased investment in field force from April in NY
- ✓ Field force continue with MODIA™ awareness campaign and initiated modiaONE trial campaign to ZUBSOLV® customers in February

ZUBSOLV® EBIT (SEK M) and EBIT margin, LTM Q1 2022



[1] Includes UHG and Humana, 7.2% marketshare if these are excluded
[2] LTM, Last Twelve Months (Q2 2021-Q1 2022)

Multiple drivers for growth

1

Covid-19 effects likely to diminish improving patient access to care and Q2-Q4 historically with improving growth rates

2

Multiple comprehensive activities on-going on federal and state levels to enable more patients access to treatment

3

Improved market access for ZUBSOLV® with Public access increasing to 48%(42%) and a slight decrease in Commercial at 98% (99%)

4

The launch of MODIA™ will open up new market segments and is highly complementary to ZUBSOLV®

HQ & Pipeline

Pharma products and development pipeline

Pharmaceuticals

Product/ Project	Exploratory	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Approved and/or Launched US	Approved and/or Launched EU	Approved and/or Launched RoW
ZUBSOLV® Opioid Use Disorder/ **sublingual platform** (accord Make it better)									
Abstral® Breaktrough Cancer Pain/ **sublingual platform** (KYOWA KIRIN)									
Edluar® Insomnia/ **sublingual platform** (Mylan)									
OX124 Naloxone, Opioid Overdose/ **amorphOX®**									
OX125 Nalmefene, Opioid Overdose/ **amorphOX®**									
OX338 Ketorolac, Moderate to moderately severe pain									
OX640 Adrenaline, allergic reactions/ **amorphOX®**									
OX-MPI Microvascular Disease (GESYNTA PHARMA AB)									

Granted orphan drug designation in April 2022

OX124 & OX125 – overdose rescue medications

- Significant health issue in the US with >107.000 deaths from overdose last 12 months
- Current US market exceeding USD 400 million
- Based on amorphOX® and designed to treat overdoses caused by synthetic opioids, such as fentanyl
- OX124 clinically differentiated to market leader and GX of market leader
- **OX124 on track to be filed with FDA in H2 2022**

Note: product image for OX125 is a prototype

OX640 – emergency treatment of allergic reactions

- First line treatment today: intramuscular auto-injectors
- OX640 offers:
  - Needle free alternative based on amorphOX®
  - Improved handling and storage (doubling shelf life of existing products)
  - No bisulfite antioxidant and preservative free
  - Improved convenience and acceptability vs injection products increases likelihood of timely use
- OX640 with excellent stability data compared to other products[1]
- **First clinical trial on track to be initiated in Q3 2022**

[1] Based on publicly available data

Orexo internal platform building on the amorphOX® technology

Validated in humans

✓ Superior pharmacokinetic properties with more rapid onset, higher peak and overall exposure, lower variability

Plasma concentration from clinical trial



Excellent stability

✓ Excellent stability even under accelerated conditions and proven to work on a broad scope of API's

Amount of API



Patent protected

✓ Three granted US patents and several patent applications have been filed with potential protection until 2042



amorphOX® works for a broad scope of drugs

Adrenaline



0.5% after 6 months

Apomorphine



0.2% after 9 months

Naloxone



≤0.1% after 12 months

Loxapine



0.2% after 12 months

Ketorolac



0.8% after 6 months

Nalmefene



≤0.1% after 15 months

Chemical degradation after accelerated stability studies at 40°C/75% RH

amorphOX® and macromolecules



Recent protein example

- ✓ Enzyme of 464 kDa (~1000 amino acids)
- ✓ Successfully formulated in the **amorphOX®** platform
- ✓ High yield
- ✓ Free-flowing powder
- ✓ Narrow particle size distribution
- ✓ Enzymatic activity fully retained after:
  - manufacturing
  - 1M storage @ 40°C/75%RH

Digital Therapeutics (DTx)

DTx in brief

- ✓ Subsection of digital health
- ✓ Evidence-based therapeutic intervention
- ✓ Prevent, manage, or treat a medical disorder or disease
- ✓ Particularly applicable in the mental illness & addiction space
- ✓ Standalone or along with pharma treatment
- ✓ Available 24/7

Strong underlying trends will force the DTx market to gain traction

Healthcare systems challenged
Aging population and sky-rocketing costs are forcing the healthcare providers to rethink how to deliver healthcare to increase efficiency and value.

Consumers (patients) in the center
Patients want to be seen as consumers and requires holistic and customized treatments with access 24/7.

Widespread technology acceptance
Covid-19 has further pushed forward the ongoing tech revolution and the use of telemedicine is pervasive.

Value-based care
Providers will be rewarded based on the ability to add patient value. Analyzing RWE data pave the way for efficient allocation of resources.

Orexo is at the leading edge of digitalization in the pursuit to take DTx from its infancy to become a natural part of healthcare

"In less than a decade, DTx companies have completely disrupted the healthcare scene for the better."

The Future of Digital Therapeutics and The Impact On Care, The Linus Group, May 2021

- ✓ **Establishing Reimbursement**
  Orexo working in tight collaboration with world leaders in digital health to make DTx accessible to all patients. However, universal reimbursement processes still to be established

- ✓ **Disruptive technology**
  Through pilot programs, trials and real world evidence collection, Orexo is working with payers and leading healthcare organizations to build confidence in the value of our DTx to healthcare.

Clinically proven DTx in collaboration with GAIA AG

Rooted in cognitive behavioral therapy techniques and based on AI technology offering a highly individualized intervention.

	modia	VORV!DA	deprexis®
Instructions for use	Opioid dependence	Alcohol misuse	Depression
Clinical evidence	Ongoing randomized clinical trial, 400 patients	Evaluated in 1 randomized clinical trial, > 600 patients	Evaluated in 13 randomized clinical trials, > 2.800 patients
Length of treatment	6 months	6 months	3 months
Treatment method	Along with current standard of care including medication	Standalone or as a complement to current standard of care	Standalone or as a complement to current standard of care
FDA clearance	Will apply for a 510 k clearance, meanwhile launched under FDA's Public Health Emergency Use Authorization (EUA)	FDA cleared under the EUA	FDA cleared under the enforcement discretion

Financial & legal

Q1 2022 LTM – A transformative period building for future growth

- **Significant investments in establishing digital therapeutics business and development of OX124**
- **Recurring business is well financed from ZUBSOLV® profit contribution**

Note: LTM, Last Twelve Months

Group net revenues
592 SEK M

US Pharma net revenues
535 SEK M

EBITDA
-134 SEK M

US Pharma EBIT
296 SEK M

Cash position
434 SEK M

US Pharma EBIT margin
55 %

Legal update – no changes in Q1 2022

ZUBSOLV® patent dispute vs Sun Pharma

No changes in Q1

- ✓ 9 patents listed in the Orange Book
- ✓ Expiring dates Dec 2027 – Sep 2032
- ✓ Previously successfully managed to defend ZUBSOLV® IP rights in the US appeal court

Subpoena with regards to ZUBSOLV®

No changes in Q1

- ✓ Very limited activities in Q1
- ✓ No additional information received since issuance of subpoena July 2020

Future value drivers

Strong value drivers for long-term growth

1

Product portfolio addressing large and growing markets

2

Leveraging our US commercial excellence

3

Expanding pipeline based on the novel proprietary technology platform amorphOX®

4

Strong cash flow generation from the US Pharma

5

Entering digital therapeutics, a new evidence-based frontier in patient care



Thanks

For more information, please visit www.orexo.com.
You can also follow Orexo at Twitter @orexoabpubl, LinkedIn and YouTube.

Headquarter Sweden, Orexo AB, P.O. Box 303, 751 05 Uppsala, Sweden, E-mail: info@orexo.com, Phone: +46 (0)18 780 88 00
Subsidiary US, Orexo US Inc. 150 Headquarters Plaza East Tower Morristown, New Jersey 07960 United States
E-mail: info-us@orexo.com, Phone: +1 (0)855 982 7658